<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05085093</url>
  </required_header>
  <id_info>
    <org_study_id>KY20212121</org_study_id>
    <nct_id>NCT05085093</nct_id>
  </id_info>
  <brief_title>Protective Efficacy of HPV Vaccination After Treatment of HPV Related Diseases</brief_title>
  <official_title>Protective Efficacy of HPV Vaccination After Treatment of HPV Related Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To understand the HPV infection status and subtype distribution of patients, and to study the&#xD;
      protective effect of prophylactic HPV vaccination on the recurrence of HPV related diseases&#xD;
      after treatment through a prospective cohort study. To provide data support for the primary&#xD;
      prevention of HPV related diseases in Chinese women after treatment, and to analyze the&#xD;
      related factors of HPV related disease recurrence and HPV continuous positive.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 18, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>recurrence</measure>
    <time_frame>6 months after operation</time_frame>
    <description>If The lesions were found again more than 6 months after operation (pathological diagnosis)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Persistent HPV infection</measure>
    <time_frame>At least 12 months</time_frame>
    <description>At least 12 months apart, cervical vaginal / external genital swabs or tissue biopsies were taken for 2 or more consecutive times, and HPV detection and analysis showed that the same HPV type was positive</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">414</enrollment>
  <condition>HPV Vaccination、HPV Related Diseases、Protective Efficacy</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <description>HPV vaccine group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>non HPV vaccine group</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HPV vaccine</intervention_name>
    <description>Patients choose to be vaccinated or not to be vaccinated with HPV vaccine according to their own wishes</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with HPV related diseases&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Women aged 18-45, of childbearing age or before perimenopause (patients without&#xD;
             pregnancy plan within two years); 2. Patients diagnosed as condyloma acuminatum,&#xD;
             vaginal intraepithelial lesions (high-grade and low-grade lesions), cervical&#xD;
             intraepithelial lesions (high-grade and low-grade lesions), vulvar intraepithelial&#xD;
             lesions (high-grade and low-grade lesions), cervical cancer (IA1-IIA2 stage) and&#xD;
             treated within 3 months; 3. No surgical contraindications such as severe center of&#xD;
             heart, lung and other organ dysfunction and abnormal hemagglutination; 4. Fully know&#xD;
             the treatment method, sign informed consent, and actively cooperate with follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Participating in other clinical trials; 2. Use immunoglobulin or blood products&#xD;
             within 3 months before vaccination; 3. Hypersensitivity to vaccine active ingredients&#xD;
             or any dressing ingredients; 4. Acute stage of moderate and severe diseases; 5. Acute&#xD;
             stage of severe immune deficiency diseases and autoimmune diseases; 6. Pregnant women&#xD;
             and lactating patients; 7. Patients with planned pregnancy within 2 years; 8. Less&#xD;
             than 18 years old and more than 45 years old.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>The diseases in this study mainly occurred in female groups</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>hong Yang, professional</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affiliated Hospital，Air Force Medical University,Xi'an, Shaanxi, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Air Force Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 17, 2021</study_first_submitted>
  <study_first_submitted_qc>October 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>We haven't decided whether to share the data yet</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

